Second, since the strength of mesenchymal signaling differs between the core region of the tumor entity and the infiltrative margin, assessing intertumoral heterogeneity accordingly would be more helpful in elucidating the complex function of FERMT2. Third, the number of included clinical samples was small, and it was necessary to collect patients in multicenter clinical queues for further analysis and validation. The gene discussed is FERMT2; the disease is neoplasm.